## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.93 indicates fundamental undervaluation. Analyst consensus $128 (+34% upside). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($92.10)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Boston Scientific Stock: Steady Beat, Subtle Volatility – What The Market Is Really Pricing In**
- Source: AD HOC NEWS | 20260104T030743 | Bullish | Relevance: 100%
- Boston Scientific's stock has outperformed the medtech sector, but recent trading shows nervousness despite optimistic analyst targets and strong one-year gains. Investors are debating if the stock remains a buy or is due for a pause as market expectations grow ambitious. The company's resilience comes from its focus on critical, non-deferrable cardiovascular interventions, strong pipeline, and successful acquisitions.

**2. JARISLOWSKY FRASER Ltd Trims Stake in Boston Scientific Corporation $BSX**
- Source: MarketBeat | 20260103T200745 | Neutral | Relevance: 100%
- JARISLOWSKY FRASER Ltd significantly reduced its holdings in Boston Scientific Corporation, selling 76,179 shares in Q3, now holding 2,192,794 shares valued at $214.1 million. Despite this, Boston Scientific reported a strong Q3 with EPS and revenue exceeding expectations, providing positive FY 2025 guidance. The company maintains an average analyst "Buy" rating with a target price of $124.85, even as institutional investors own 89.07% of the stock and insiders have recently sold shares.

**3. Boston Scientific Corp Is Quietly Winning Wall Street – But Is BSX Actually Worth Your Money?**
- Source: AD HOC NEWS | 20260103T020858 | Bullish | Relevance: 100%
- Boston Scientific Corp (BSX) is gaining traction on Wall Street, despite not being a mainstream viral sensation. The article explores whether this medical tech giant is a worthwhile investment, highlighting its robust med-tech pipeline, alignment with healthcare megatrends, and consistent stock performance. It concludes that BSX is a strong contender for long-term investors seeking stable growth in the healthcare technology sector.

**4. Boston Scientific Stock: Steady Beat, Subtle Volatility – What The Market Is Really Pricing In**
- Source: AD HOC NEWS | 20260104T025356 | Somewhat-Bullish | Relevance: 98%
- Boston Scientific's stock has shown a steady uptrend over the past ninety days, reflecting resilient demand and a strong pipeline, leading to significant one-year gains for investors. Despite this bullish trend, the stock has experienced subtle volatility and consolidation recently, indicating that the market is now more selective and pricing in future growth while analysts remain largely favorable with moderate upside targets. The company's future trajectory will hinge on continued clinical and regulatory milestones, successful integration of acquisitions, and the broader healthcare spending environment.

**5. The Truth About Medtronic plc: Is This ‘Boring’ Stock Actually a Silent Flex?**
- Source: AD HOC NEWS | 20260105T080832 | Neutral | Relevance: 63%
- Medtronic plc is presented as a medical technology giant that, while not a "meme stock," is a significant player in healthcare. The article explores whether this "boring" stock is a valuable long-term investment, examining its business, market perception, and risks. It concludes that Medtronic is a stable, dividend-paying company suited for core portfolios rather than speculative, high-volatility trading.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $120 | $130 | -8% |
| 2025-12-17 | Canaccord Genui | $131 | $132 | -1% |
| 2025-12-17 | RBC Capital | $130 | $125 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | Canaccord Genui | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 8 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Long-term trend broken: trading 5.3% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.93 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $141.5B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.93 |
| Forward P/E | 27.5 |
| Current P/E | 31.5 |
| YoY Growth | 14.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.8% over 5 days). Below STRENGTH zone by 3.3pp (needs >4.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 47. OFD pattern: +MLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.68% (CS: 50) | Neutral |
| RSI_14 | 46.9 | Neutral |
| MACD Histogram | 0.23 | Bullish |
| vs SMA20 | 1.008x | Above |
| vs SMA50 | 0.974x | Below |
| vs SMA200 | 0.947x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $95.50
- **Stop Loss:** $92.10 (3.6% risk)
- **Target:** $102.30 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 253
- **Position Value:** $24,161.50
- **Portfolio %:** 24.16%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*